Your session is about to expire
← Back to Search
89Zr-DFO-nimotuzumab for Lung and Colorectal Cancer
Study Summary
This trial aims to show that a certain imaging technique can help doctors better understand how aggressive a cancer is and if a patient will respond to a certain treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have never been treated with anti-EGFR antibodies.My cancer has a tumor or spread that is at least 1.5 cm big.My cancer is EGFR-positive, as confirmed by a specialist.I am between 18 and 80 years old.I can take care of myself and perform light activities.I am not pregnant or nursing, and if I can have children, I tested negative for pregnancy recently.I cannot stay still for 60 minutes during a PET scan.
- Group 1: Establish Cold Dose
- Group 2: Establish Imaging Time
- Group 3: Diagnostic Quality
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research experiment open to individuals of a youthful age?
"This medical trial seeks to enrol those aged 18 or over but less than 80."
How many participants are eligible for this scientific trial?
"Affirmative, the information hosted on clinicaltrials.gov indicates that this scientific experiment is currently enlisting participants. This study was initially publicized on February 1st 2020 and most recently revised on May 18th 2022. The research necessitates 14 individuals from one medical facility to complete it."
Is there an ongoing recruitment process for this experiment?
"Per the records on clinicaltrials.gov, this medical trial is actively accruing patients since its initial posting on February 1st 2020 and most recent update occurring May 18th 2022."
What prior experimentation has taken place surrounding 1 mg 89Zr-DFO-Nimotuzumab?
"At present, 21 clinical trials researching 1 mg 89Zr-DFO-Nimotuzumab are in progress with 6 of them being in the Phase 3 stage. These studies are mainly centered around Changsha, Hunan but can also be found at 65 different locations globally."
What criteria must be met to qualify for participation in this experiment?
"This clinical trial requires participants to have colorectal cancer and be between 18-80 years old. A total of 14 individuals are sought for this research endeavor."
What conditions can be treated with the 1 mg 89Zr-DFO-Nimotuzumab dosage?
"Clinicians are utilizing 1 mg 89Zr-DFO-Nimotuzumab to treat relapsing cases and advanced head & neck cancer, glioblastoma multiforme (GBM), and carcinomas."
Share this study with friends
Copy Link
Messenger